Literature DB >> 23430706

Effect of time since exposure to Chlamydia trachomatis on chlamydia antibody detection in women: a cross-sectional study.

Patrick J Horner1, Gillian S Wills, Rosy Reynolds, Anne M Johnson, David A Muir, Alan Winston, Andrew J Broadbent, David Parker, Myra O McClure.   

Abstract

OBJECTIVES: To investigate what factors influence the detection of Chlamydia trachomatis antibody following genital tract infection.
METHODS: One hundred and sixty-four women with a previous history of C trachomatis infection contributed to an earlier report on the performance of chlamydia antibody ELISA assays. We undertook further analysis to explore how chlamydia antibody assay sensitivity changes with time since infection.
RESULTS: Chlamydia antibody was detected in more women soon after the last detection of chlamydia at the lower genital tract than at later times. This holds true for all tests, but the Anilabsystems IgG EIA, Medac pELISA plus ELISA and the Savyon SeroCT-IgG ELISA were less sensitive than the pgp3 ELISA and the Anilabsystems microimmunofluorescence (MIF) assay at all time points except during current infection. Fall in seropositivity in women generally occurred in the early weeks and months following the last episode of chlamydia infection. There was no clear pattern of further reduction in seropositivity after 6 months. Multiple previous episodes were associated with increased seropositivity in the pgp3 assay (two or more vs one, OR 19, p<0.001) and other tests, but the effect was significantly smaller for the Anilabs, Medac and SeroCT MOMP peptide ELISAs, but not for the MIF assay.
CONCLUSIONS: Chlamydia antibody detection decreases with time since infection and this is most apparent in the first 6 months. In women who have had more than one infection, antibody remained detectable longer for all tests, but this was more marked for the pgp3 ELISA and MIF assay.

Entities:  

Keywords:  Antibodies; Chlamydia Serology; Chlamydia Trachomatis; Seroprevalence

Mesh:

Substances:

Year:  2013        PMID: 23430706     DOI: 10.1136/sextrans-2011-050386

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  28 in total

1.  Antibody to Chlamydia trachomatis proteins, TroA and HtrA, as a biomarker for Chlamydia trachomatis infection.

Authors:  K Hokynar; S Korhonen; P Norja; J Paavonen; M Puolakkainen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-14       Impact factor: 3.267

Review 2.  Advancing the public health applications of Chlamydia trachomatis serology.

Authors:  Sarah C Woodhall; Rachel J Gorwitz; Stephanie J Migchelsen; Sami L Gottlieb; Patrick J Horner; William M Geisler; Catherine Winstanley; Katrin Hufnagel; Tim Waterboer; Diana L Martin; Wilhelmina M Huston; Charlotte A Gaydos; Carolyn Deal; Magnus Unemo; J Kevin Dunbar; Kyle Bernstein
Journal:  Lancet Infect Dis       Date:  2018-07-05       Impact factor: 25.071

3.  Maternal Antibodies to Chlamydia trachomatis and Risk of Gastroschisis.

Authors:  Samantha E Parker; Martha M Werler; Mika Gissler; Heljä-Marja Surcel
Journal:  Birth Defects Res       Date:  2017-02-24       Impact factor: 2.344

Review 4.  What Can Serology Tell Us About the Burden of Infertility in Women Caused by Chlamydia?

Authors:  Patrick J Horner; Gloria E Anyalechi; William M Geisler
Journal:  J Infect Dis       Date:  2021-08-16       Impact factor: 5.226

5.  Persistence of Trichomonas vaginalis serostatus in men over time.

Authors:  Siobhan Sutcliffe; John F Alderete; Calvin Neace; Patrick A Joyce; Charlotte A Gaydos; James I A Huth; Lorelei A Mucci; Lisa B Signorello
Journal:  Cancer Causes Control       Date:  2015-07-30       Impact factor: 2.506

6.  Comparison of three serological assays to measure antibody response to Chlamydia antigen Pgp3 in adolescent and young adults with pelvic inflammatory disease.

Authors:  Laura Dize; Diana Martin; Sarah Gwyn; Jamie Perin; Charlotte Gaydos; Maria Trent
Journal:  Int J STD AIDS       Date:  2018-07-27       Impact factor: 1.359

7.  C. trachomatis Pgp3 antibody prevalence in young women in England, 1993-2010.

Authors:  Paddy Horner; Kate Soldan; Sueli M Vieira; Gillian S Wills; Sarah C Woodhall; Richard Pebody; Anthony Nardone; Elaine Stanford; Myra O McClure
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

8.  High Plasmid Gene Protein 3 (Pgp3) Chlamydia trachomatis Seropositivity, Pelvic Inflammatory Disease, and Infertility Among Women, National Health and Nutrition Examination Survey, United States, 2013-2016.

Authors:  Gloria E Anyalechi; Jaeyoung Hong; Damien C Danavall; Diana L Martin; Sarah E Gwyn; Patrick J Horner; Brian H Raphael; Robert D Kirkcaldy; Ellen N Kersh; Kyle T Bernstein
Journal:  Clin Infect Dis       Date:  2021-10-20       Impact factor: 20.999

9.  Seroprevalence of Chlamydia trachomatis Among Female Adults in the United States: The National Health and Nutrition Examination Surveys.

Authors:  Molly R Petersen; Eshan U Patel; M Kate Grabowski; Charlotte A Gaydos; Thomas C Quinn; Aaron A R Tobian
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

10.  Chlamydial Pgp3 Seropositivity and Population-Attributable Fraction Among Women With Tubal Factor Infertility.

Authors:  Gloria E Anyalechi; Jaeyoung Hong; Robert D Kirkcaldy; Harold C Wiesenfeld; Paddy Horner; Gillian S Wills; Myra O McClure; Karen R Hammond; Catherine L Haggerty; Dmitry M Kissin; Edward W Hook; Michael P Steinkampf; Kyle Bernstein; William M Geisler
Journal:  Sex Transm Dis       Date:  2021-03-31       Impact factor: 3.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.